cp-547632
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2002 (NCT00074854)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1- Mol. weight
- 532.41 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL253969 ↗
Also known as
- 3-(4-bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide
- cp547632
- cp 547632
- cp 547,632
- cp-547632
- cp-547632
- cp-547632
- cp-547632
- cp-547,632
- cp-547,632
- cp-547,632
- cp547,632
- osi-632
- osi-632
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00096239 | Phase 2 | Dec 1, 2004 | National Cancer Institute (NCI), University of California, Los Angeles |
| NCT00074867 | Phase 2 | Oct 1, 2003 | Pfizer |
| NCT00074854 | Phase 1/Phase 2 (Phase 2) | May 1, 2002 | Pfizer |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 2 | 2 | 1 | 2002 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2004 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2004 |
3 organizations
Page 1 / 1